Arqule Inc. buy stratec
Startpreis
01.11.18
/
50%
3,16 €
Kursziel
07.03.19
6,31 €
Rendite (%)
36,57 %
Endpreis
07.03.19
4,31 €
Zusammenfassung
Diese Einschätzung wurde am 07.03.19 mit einem Endkurs von 4,31 € beendet. Satte Gewinne von 36,57 % verzeichnete die BUY Einschätzung von stratec. stratec hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Arqule Inc. | - | - | - | - |
| iShares Core DAX® | 0,05 % | 5,59 % | 14,40 % | 19,77 % |
| iShares Nasdaq 100 | 1,81 % | 7,45 % | 34,92 % | 57,24 % |
| iShares Nikkei 225® | 2,18 % | 2,82 % | 11,12 % | 8,87 % |
| iShares S&P 500 | 1,04 % | 4,97 % | 27,63 % | 48,79 % |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Arqule Inc. diskutieren
Arqule is reissued as a Buy with a $7 price target at Roth Capital
with the following commentary this morning:
"We believe that the ArQule of 4Q is a more valuable company than the ArQule of 3Q (which, in turn, was
more valuable than the and we remain high-conviction buyers both in
light of the recent pullback in share price and in anticipation of the
data update at ASH in December. Status update on the BTK inhibitor
ARQ531. At EHA’18, ArQule showed positive safety and tumor reduction
data in three cohorts from its 15mg QD). Subsequently, the company put
in place two protocol amendments which, in our view, increase the
potential depth of the eventual dataset: (1) intra-patient
dose-escalation (could provide evidence of dose- dependent clinical
benefit); (2) reduction of washout period to 5X the half-life of the
last administered drug (could soften the prognostics of the advanced
patients being recruited).”
(Vom Mitglied beendet)